Physician profile
Daniel R Seward
NPI 1326464017
$1,701.54
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $577 · 2023: $479 · 2024: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $235.78 | 2021-2023 | |
| Abbvie INC. | $221.61 | 2023-2024 | |
| Abbott Laboratories | $191.94 | 2022-2024 | Freestyle Libre 3 |
| Neurelis, INC. | $191.93 | 2022-2023 | Valtoco |
| Axsome Therapeutics, INC. | $124.87 | 2024 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $121.81 | 2023 | Dupixent |
| Alexion Pharmaceuticals, INC. | $121.81 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $105.84 | 2021 | |
| Gilead Sciences, INC. | $97.46 | 2022 | |
| Cardiovascular Systems INC. | $96.29 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.34 | 2022 | |
| Lundbeck LLC | $49.28 | 2023 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $48.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Seward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.